These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141 [TBL] [Abstract][Full Text] [Related]
6. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577 [TBL] [Abstract][Full Text] [Related]
7. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329 [TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319 [TBL] [Abstract][Full Text] [Related]
9. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients. Ochsenreither S; Fusi A; Geikowski A; Stather D; Busse A; Stroux A; Letsch A; Keilholz U Cancer Immunol Immunother; 2012 Mar; 61(3):313-22. PubMed ID: 21898091 [TBL] [Abstract][Full Text] [Related]
10. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188 [TBL] [Abstract][Full Text] [Related]
11. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Romano E; Rossi M; Ratzinger G; de Cos MA; Chung DJ; Panageas KS; Wolchok JD; Houghton AN; Chapman PB; Heller G; Yuan J; Young JW Clin Cancer Res; 2011 Apr; 17(7):1984-97. PubMed ID: 21355077 [TBL] [Abstract][Full Text] [Related]
13. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Savage P; Gao L; Vento K; Cowburn P; Man S; Steven N; Ogg G; McMichael A; Epenetos A; Goulmy E; Stauss HJ Blood; 2004 Jun; 103(12):4613-5. PubMed ID: 14988155 [TBL] [Abstract][Full Text] [Related]
14. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Tsuboi A; Oka Y; Udaka K; Murakami M; Masuda T; Nakano A; Nakajima H; Yasukawa M; Hiraki A; Oji Y; Kawakami M; Hosen N; Fujioka T; Wu F; Taniguchi Y; Nishida S; Asada M; Ogawa H; Kawase I; Sugiyama H Cancer Immunol Immunother; 2002 Dec; 51(11-12):614-20. PubMed ID: 12439606 [TBL] [Abstract][Full Text] [Related]
15. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Rezvani K; Brenchley JM; Price DA; Kilical Y; Gostick E; Sewell AK; Li J; Mielke S; Douek DC; Barrett AJ Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8799-807. PubMed ID: 16361568 [TBL] [Abstract][Full Text] [Related]
16. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope. Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835 [TBL] [Abstract][Full Text] [Related]
17. WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS. Suwabe T; Shibasaki Y; Sato H; Tamura S; Katagiri T; Nemoto H; Kasami T; Kozakai T; Nanba A; Kitajima T; Fuse K; Ushiki T; Sone H; Narita M; Masuko M Int J Hematol; 2021 May; 113(5):723-734. PubMed ID: 33502734 [TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro]. Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063 [TBL] [Abstract][Full Text] [Related]
19. Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA‑A2‑restricted WT1‑reactive CD8+ T cells. Kan S; Bito T; Shimabuku M; Taguchi J; Ohkusa T; Shimodaira S; Sugiyama H; Koido S Int J Oncol; 2020 Oct; 57(4):1047-1056. PubMed ID: 32945369 [TBL] [Abstract][Full Text] [Related]
20. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]